Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Net Income (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Net Income readings, the most recent being -$4.1 million for Q1 2026.

  • On a quarterly basis, Net Income fell 110.91% to -$4.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$42.2 million, a 169.83% decrease, with the full-year FY2025 number at -$49000.0, up 99.94% from a year prior.
  • Net Income hit -$4.1 million in Q1 2026 for Atara Biotherapeutics, up from -$36.1 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $38.0 million in Q1 2025 to a low of -$88.1 million in Q1 2022.
  • Median Net Income over the past 5 years was -$31.8 million (2024), compared with a mean of -$35.0 million.
  • Biggest five-year swings in Net Income: crashed 485.08% in 2023 and later soared 219.71% in 2025.
  • Atara Biotherapeutics' Net Income stood at -$74.7 million in 2022, then grew by 18.72% to -$60.7 million in 2023, then surged by 79.09% to -$12.7 million in 2024, then plummeted by 184.75% to -$36.1 million in 2025, then soared by 88.53% to -$4.1 million in 2026.
  • The last three reported values for Net Income were -$4.1 million (Q1 2026), -$36.1 million (Q4 2025), and -$4.3 million (Q3 2025) per Business Quant data.